Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer
Background Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunoth...
Gespeichert in:
| Veröffentlicht in: | Prostate cancer and prostatic diseases 2021-09, Vol.24 (3), p.767-774 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 774 |
|---|---|
| container_issue | 3 |
| container_start_page | 767 |
| container_title | Prostate cancer and prostatic diseases |
| container_volume | 24 |
| creator | Amori, Gulanbar Sugawara, Emiko Shigematsu, Yasuyuki Akiya, Masashi Kunieda, Junko Yuasa, Takeshi Yamamoto, Shinya Yonese, Junji Takeuchi, Kengo Inamura, Kentaro |
| description | Background
Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer.
Methods
We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer.
Results
High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%;
p
= 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72;
p
= 0.047) and overall mortality rates (multivariable HR = 2.04;
p
= 0.025).
Conclusions
Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment. |
| doi_str_mv | 10.1038/s41391-021-00331-6 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2487750051</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A673073097</galeid><sourcerecordid>A673073097</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-f45902161a9c890dcc7ec9c8ae619ad474ece5252edd9703649cf7598f4578023</originalsourceid><addsrcrecordid>eNp9kl1v1iAUxxujcXP6BbwwJCbGm25QCpTLuahbsmQ385owevo8LC1UDt3ct5f6TLcZY4BwAr__gfNSVW8ZPWSUd0fYMq5ZTZuyKOesls-qfdYqWQtJu-fF5lLUqhPNXvUK8ZpSqpmmL6s9zoXopOT7VbhcppjIJ1WfcgI_5gSIPgbiA-m93YSI2Tty5eOMdwRncH6CgMSGnuCSbvyNHVd2ttlDyEhufd6SCbLFbFflnOJqAXE2OEivqxeDHRHe3O8H1bcvny9PTuvzi69nJ8fntWsVz_XQCl3Cksxq12naO6fAFdOCZNr2rWrBgWhEA32vFeWy1W5QQndFqDra8IPq485vef_7ApjN5NHBONoAcUHTtJ1SglLBCvr-L_Q6LimU35lGSK65bDrxQG3sCMaHIeZk3erUHEvFaZlaFerwH1QZPUzexQCDL-dPBB8eCbZgx7zFOC651ACfgs0OdCWhmGAwc_KTTXeGUbN2g9l1gylpM7-6wcgiencf2nI1Qf9H8rv8BeA7AMtV2EB6iP0_bn8CT8q9hA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2563936285</pqid></control><display><type>article</type><title>Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Amori, Gulanbar ; Sugawara, Emiko ; Shigematsu, Yasuyuki ; Akiya, Masashi ; Kunieda, Junko ; Yuasa, Takeshi ; Yamamoto, Shinya ; Yonese, Junji ; Takeuchi, Kengo ; Inamura, Kentaro</creator><creatorcontrib>Amori, Gulanbar ; Sugawara, Emiko ; Shigematsu, Yasuyuki ; Akiya, Masashi ; Kunieda, Junko ; Yuasa, Takeshi ; Yamamoto, Shinya ; Yonese, Junji ; Takeuchi, Kengo ; Inamura, Kentaro</creatorcontrib><description>Background
Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer.
Methods
We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer.
Results
High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%;
p
= 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72;
p
= 0.047) and overall mortality rates (multivariable HR = 2.04;
p
= 0.025).
Conclusions
Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.</description><identifier>ISSN: 1365-7852</identifier><identifier>EISSN: 1476-5608</identifier><identifier>DOI: 10.1038/s41391-021-00331-6</identifier><identifier>PMID: 33558663</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/67/589/466 ; 692/53/2422 ; 82/51 ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; B7 Antigens - metabolism ; Biomarkers ; Biomarkers, Tumor - metabolism ; Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer patients ; Cancer Research ; Diagnostic systems ; Follow-Up Studies ; Health services ; Humans ; Immune checkpoint ; Immunotherapy ; Japan ; Male ; Metastases ; Metastasis ; Mortality ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Patient outcomes ; Patients ; Prognosis ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - mortality ; Prostatic Neoplasms - pathology ; Reproductive Medicine ; Survival ; Survival Rate ; Tumors</subject><ispartof>Prostate cancer and prostatic diseases, 2021-09, Vol.24 (3), p.767-774</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-f45902161a9c890dcc7ec9c8ae619ad474ece5252edd9703649cf7598f4578023</citedby><cites>FETCH-LOGICAL-c473t-f45902161a9c890dcc7ec9c8ae619ad474ece5252edd9703649cf7598f4578023</cites><orcidid>0000-0001-6444-3861</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41391-021-00331-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41391-021-00331-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33558663$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Amori, Gulanbar</creatorcontrib><creatorcontrib>Sugawara, Emiko</creatorcontrib><creatorcontrib>Shigematsu, Yasuyuki</creatorcontrib><creatorcontrib>Akiya, Masashi</creatorcontrib><creatorcontrib>Kunieda, Junko</creatorcontrib><creatorcontrib>Yuasa, Takeshi</creatorcontrib><creatorcontrib>Yamamoto, Shinya</creatorcontrib><creatorcontrib>Yonese, Junji</creatorcontrib><creatorcontrib>Takeuchi, Kengo</creatorcontrib><creatorcontrib>Inamura, Kentaro</creatorcontrib><title>Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer</title><title>Prostate cancer and prostatic diseases</title><addtitle>Prostate Cancer Prostatic Dis</addtitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><description>Background
Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer.
Methods
We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer.
Results
High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%;
p
= 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72;
p
= 0.047) and overall mortality rates (multivariable HR = 2.04;
p
= 0.025).
Conclusions
Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.</description><subject>631/67/589/466</subject><subject>692/53/2422</subject><subject>82/51</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>B7 Antigens - metabolism</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer patients</subject><subject>Cancer Research</subject><subject>Diagnostic systems</subject><subject>Follow-Up Studies</subject><subject>Health services</subject><subject>Humans</subject><subject>Immune checkpoint</subject><subject>Immunotherapy</subject><subject>Japan</subject><subject>Male</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Mortality</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - mortality</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Reproductive Medicine</subject><subject>Survival</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>1365-7852</issn><issn>1476-5608</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kl1v1iAUxxujcXP6BbwwJCbGm25QCpTLuahbsmQ385owevo8LC1UDt3ct5f6TLcZY4BwAr__gfNSVW8ZPWSUd0fYMq5ZTZuyKOesls-qfdYqWQtJu-fF5lLUqhPNXvUK8ZpSqpmmL6s9zoXopOT7VbhcppjIJ1WfcgI_5gSIPgbiA-m93YSI2Tty5eOMdwRncH6CgMSGnuCSbvyNHVd2ttlDyEhufd6SCbLFbFflnOJqAXE2OEivqxeDHRHe3O8H1bcvny9PTuvzi69nJ8fntWsVz_XQCl3Cksxq12naO6fAFdOCZNr2rWrBgWhEA32vFeWy1W5QQndFqDra8IPq485vef_7ApjN5NHBONoAcUHTtJ1SglLBCvr-L_Q6LimU35lGSK65bDrxQG3sCMaHIeZk3erUHEvFaZlaFerwH1QZPUzexQCDL-dPBB8eCbZgx7zFOC651ACfgs0OdCWhmGAwc_KTTXeGUbN2g9l1gylpM7-6wcgiencf2nI1Qf9H8rv8BeA7AMtV2EB6iP0_bn8CT8q9hA</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Amori, Gulanbar</creator><creator>Sugawara, Emiko</creator><creator>Shigematsu, Yasuyuki</creator><creator>Akiya, Masashi</creator><creator>Kunieda, Junko</creator><creator>Yuasa, Takeshi</creator><creator>Yamamoto, Shinya</creator><creator>Yonese, Junji</creator><creator>Takeuchi, Kengo</creator><creator>Inamura, Kentaro</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6444-3861</orcidid></search><sort><creationdate>20210901</creationdate><title>Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer</title><author>Amori, Gulanbar ; Sugawara, Emiko ; Shigematsu, Yasuyuki ; Akiya, Masashi ; Kunieda, Junko ; Yuasa, Takeshi ; Yamamoto, Shinya ; Yonese, Junji ; Takeuchi, Kengo ; Inamura, Kentaro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-f45902161a9c890dcc7ec9c8ae619ad474ece5252edd9703649cf7598f4578023</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>631/67/589/466</topic><topic>692/53/2422</topic><topic>82/51</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>B7 Antigens - metabolism</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer patients</topic><topic>Cancer Research</topic><topic>Diagnostic systems</topic><topic>Follow-Up Studies</topic><topic>Health services</topic><topic>Humans</topic><topic>Immune checkpoint</topic><topic>Immunotherapy</topic><topic>Japan</topic><topic>Male</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Mortality</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - mortality</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Reproductive Medicine</topic><topic>Survival</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Amori, Gulanbar</creatorcontrib><creatorcontrib>Sugawara, Emiko</creatorcontrib><creatorcontrib>Shigematsu, Yasuyuki</creatorcontrib><creatorcontrib>Akiya, Masashi</creatorcontrib><creatorcontrib>Kunieda, Junko</creatorcontrib><creatorcontrib>Yuasa, Takeshi</creatorcontrib><creatorcontrib>Yamamoto, Shinya</creatorcontrib><creatorcontrib>Yonese, Junji</creatorcontrib><creatorcontrib>Takeuchi, Kengo</creatorcontrib><creatorcontrib>Inamura, Kentaro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Prostate cancer and prostatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Amori, Gulanbar</au><au>Sugawara, Emiko</au><au>Shigematsu, Yasuyuki</au><au>Akiya, Masashi</au><au>Kunieda, Junko</au><au>Yuasa, Takeshi</au><au>Yamamoto, Shinya</au><au>Yonese, Junji</au><au>Takeuchi, Kengo</au><au>Inamura, Kentaro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer</atitle><jtitle>Prostate cancer and prostatic diseases</jtitle><stitle>Prostate Cancer Prostatic Dis</stitle><addtitle>Prostate Cancer Prostatic Dis</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>24</volume><issue>3</issue><spage>767</spage><epage>774</epage><pages>767-774</pages><issn>1365-7852</issn><eissn>1476-5608</eissn><abstract>Background
Prostate cancer spans a broad spectrum from indolent to deadly disease. In the management of prostate cancer, diagnostic biopsy specimens are important sources of data that inform the selection of treatment. B7-H3 (CD276), an immune checkpoint molecule, has emerged as a promising immunotherapy target. B7-H3 expression is related to adverse clinical outcomes in various types of cancer; however, little is known concerning the association between tumor B7-H3 expression in diagnostic biopsy specimens and clinical outcome in patients with metastatic prostate cancer.
Methods
We evaluated tumor B7-H3 expression levels in diagnostic biopsy specimens from 135 patients with metastatic prostate cancer and 113 patients with localized prostate cancer.
Results
High B7-H3 expression was more frequently observed in patients with metastatic cancer than in those with localized cancer (31 vs. 12%;
p
= 0.0003). In patients with localized cancer, the B7-H3 expression status was not associated with biochemical recurrence-free survival. However, among patients with metastatic cancer, high B7-H3 expression was independently associated with high disease-specific mortality (multivariable hazard ratio [HR] = 2.72;
p
= 0.047) and overall mortality rates (multivariable HR = 2.04;
p
= 0.025).
Conclusions
Tumor B7-H3 expression in diagnostic biopsy specimens may be a useful biomarker for identifying highly aggressive metastatic prostate cancer. Given the potential utility of anti-B7-H3 immunotherapy, this information may aid in stratifying prostate cancer based on its responsiveness to B7-H3-targeted treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33558663</pmid><doi>10.1038/s41391-021-00331-6</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-6444-3861</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1365-7852 |
| ispartof | Prostate cancer and prostatic diseases, 2021-09, Vol.24 (3), p.767-774 |
| issn | 1365-7852 1476-5608 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2487750051 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | 631/67/589/466 692/53/2422 82/51 Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7 Antigens - metabolism Biomarkers Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Biopsy Cancer patients Cancer Research Diagnostic systems Follow-Up Studies Health services Humans Immune checkpoint Immunotherapy Japan Male Metastases Metastasis Mortality Neoplasm Metastasis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Patient outcomes Patients Prognosis Prostate cancer Prostatic Neoplasms - drug therapy Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Reproductive Medicine Survival Survival Rate Tumors |
| title | Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T20%3A11%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tumor%20B7-H3%20expression%20in%20diagnostic%20biopsy%20specimens%20and%20survival%20in%20patients%20with%20metastatic%20prostate%20cancer&rft.jtitle=Prostate%20cancer%20and%20prostatic%20diseases&rft.au=Amori,%20Gulanbar&rft.date=2021-09-01&rft.volume=24&rft.issue=3&rft.spage=767&rft.epage=774&rft.pages=767-774&rft.issn=1365-7852&rft.eissn=1476-5608&rft_id=info:doi/10.1038/s41391-021-00331-6&rft_dat=%3Cgale_proqu%3EA673073097%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2563936285&rft_id=info:pmid/33558663&rft_galeid=A673073097&rfr_iscdi=true |